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Chapter l0
The use of curare in 25 patients by Harold Griffith and Enid Johnson in 1942
changed anesthetic practice throughout the world and heralded the start of the
modern era of anesthesiology. The introduction of curare allowed adequate muscle
relaxation at a lighter, and therefore better-tolerated, degree of general anesthesia.
It would be hard to imagine if and how, without the introduction of neuromuscular
blocking agents (NMBA's), open heart-, transplant-, or intracranial surgery could
have developed.
Whereas the peroperative surgical and anesthetic conditions are greatly
improved by the use of modern non-depolarizing NMBA's, anesthesiologists are
still faced with two problems: how to secure the airway of a non-fasted patient
rapidly using a non-depolarizing NMBA and how to prevent residual curarisation
at the end of the surgical procedure. Both problerns relate to aspects of the time
course of action, i.e. the onset and the offset, respectively. Time course of action on
its turn is mainly detennined by the pharmacokinetics of the NMBA's since the
interaction betrveen NMBA's and the acetylcholine receptor is extremely fast and
binding to the receptors almost immediately results in paralysis of the particular
muscle fiber(s). Consequently, in order to understand the factors determining the
onset and offset of block we have to know the factors that determine the
phannacokinetics of NMBA's. Therefore, our central question was; whal happens
following intravenous administration of a NMBA? The aim of the research
described in this thesis was to investigate the influence of the lung and the liver on
the pharmacokinetics and time course of action of NMBA's.
For several reasons, the lung is capable of influencing the early
pharmacokinetics of NMBA's. Not only is the lung interposed between the site of
drug administration and the site of effect, the lungs also receive the entire cardiac
output and are equipped rvith the largest capillary surface area in the body. Because
the lungs receive the entire cardiac output, even a small pulmonary extraction ratio
could account for the transient storage of a significant part of the injected dose.
Moreover, the lungs have shown to be able to (temporarily) store a variety of basic
drugs, among which are opioids and propofol. Since NMBA's are basic amines it is
possible that also NMBA's undergo pulmonary uptake and storage. Until now, the
role of the lung in the pharmacokinetics of NMBA's has been neglected.
Therefore, we developed an isolated in situ heart-lung preparation in the cat to
study this aspect of the disposition of NMBA's (Chapter 3). Validation of the
model showed complele isolation of the organs without major biochemical changes
or edema and a stable muscle response. Pilot experiments performed in this model
showed a slow decay in the plasma concentration of rocuronium and Org7617,
making a prominent role for the lung in the pharmacokinetics of NMBA's unlikely.
To study the role of the lung in the onset of the neuromuscular blocking effect,
we determined the pulmonary first-pass uptake of NMBA's. If substantial
pulmonary first-pass uptake occurs. the question arises whether differences in
potency and/or onset time between agents could at least to some extent be related
to differences in pulmonary first-pass uptake. Therefore, the pulmonary first-pass
uptake of five NMBA's, that have diverse potencies and/or onset times, were
studied in the pig (chapter 4). Substantial first-pass uptake of rocuronium,
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vecuronium, Org 9487, Org 7617 or d-tubocurarine by the lung did not occur.
Since we selected NMBA's which differ in potency up to a factor of 30 and differ
in onset time up to a factor of 2, this uptake study shows that differences in potency
and onset time between NMBA's in vivo cannot, not even in part, be explained by
differences in puhnonary first-pass uptake.
Since we chose to study the factors that determine the onset of action, the early
pharmacokinetics of NMBA's should be unravelled in more detail. However, in
pharmacokinetic and pharmacokinetic/pharmacodynamic (PK/PD) rnodelling
studies the first blood sample (arterial or venous) is usually taken one or more
minute(s) after drug administration. Since actual data on the early time course of
the plasma concentration are lacking, investigators have to extrapolate the plasma
concentration to time zero assuming instantaneous and complete mixing, and use
this extrapolated plasma concentration profile for pharmacokinetic analysis and
PK/PD modelling. For several reasons this extrapolation is incorrect. Therefore, r,ve
raised the following question: do plasma concentrations obtained from early
arterial blood sampling improve PK/PD modelling? To answer this question we
determined the influence of inclusion of experimental data obtained from early
arterial sampling on PK/PD modelling. The concentration in the effect
compartment at 50o/o block (EC:o) based on extensive modelling of data obtained
from early arterial sampling was calculated for a series of NMBA's. In addition,
the EC-5s derived from modell ing was compared to the measured concentration in
plasma during a steady state 50%o block (Cp5e55) (Chapter 5). As expected, a high
peak concentration in the arÍerial blood was seen within 20 s after administration of
the NMBA. 'fhis confirrned that the mixing of the NMBA in the central volume of
distribution is indeed far from complete. Extensive PK/PD modelling revealed that
plasma concentrations obtained from early arterial blood sarnpling can irnprove
PK,PD modelling. Independent of the rype of modelling, the EC5s and k"s (rate
constant for equilibration with the effect compartment) based on data sets
including early arÍerial blood sampling were. for all five NMBA's, significantly
higher and lower, respectively, than those based on data sets obtained from usual
sampling, i.e. from I or 2 min after adrninistration of the NMBA. Hor.vever, the
goodness of fit was not entirely satisfactory, suggesting that the PK/PD model
could not adequatel"v" describe the relationship between the rapidly changing plasma
concentration during the first minute afier administration and the effect. Usually,
the Sheiner link model is used to correlate the concentration profile in the effect
compartment to the modelled plasma concentration profile which is smoothened
due to extrapolation of the plasma concentration to time zero. The true plasma
concentration profile, however. is not smooth at all. Therefore, rve developed an
interstitial link model consisting of an effect compartment that is linked to an
interstitial compartment interposed between the plasma compartment and the effect
compartment. Although the interstitial link model improved the goodness of fit,
there is an identifiability problem hampering the interpretation of the results.
PK/PD analysis revealed that a parametric pharmacodynamic (sigmoid E-u*) model
could not describe the time course of effect of the NMBA's adequatelv. Our results
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may implicate that for PK/I'D modelling, depending on the question to be
answered, early arterial sampling should be considered.
With regard to the onset of neuromuscular block the liver plays an important
role in the pharmacokinetics of NMBA's. The liver synthesizes plasma
cholinesterase and other plasma esterases that play a crucial role in the enzymic
degradation of some NMBA's. Thus far, the factors that determine the onset time
are not fully known. On the basis of in vitro studies, differences in receptor affinity
were suggested to account for the differences in onset time between NMBA's.
Since a rapid decrease in the concentration of a NMBA in plasma, due to a high
rate in early distribution or elimination of NMBA from plasma, results in a rapid
equilibration of the NMBA between plasma and biophase, we hypothesized that the
rate of decrease in the plasma concentration of a NMBA influences the onset time
of neuromuscular block. To test the hypothesis, we inhibited the enzymic
degradation of suxamethonium and of mivacurium by means of a selective plasma
cholinesterase-inhibitor, thus decreasing the rate of disappearance of the NMBA
from plasma (Chapter 6). The hypothesis was found to be valid: inhibition of the
enzymic degradation of suxamethonium and mivacurium increased the onset time
of block and decreased the EDTS of both agents. Therefore, pharmacokinetics
influences the onset time of neuromuscular block. Our results imply that in order to
obtain an ultrashort onset time, i.e. one minute or less, NMBA's should be
developed which not only have a low affiniff for the receptor, but also should
disappear from plasma rapidly.
Also with regard to the offset of neuromuscular block, the liver is an important
organ for the pharmacokinetics of NMBA's. Substantial amounts of many steroidal
NMBA's are taken up into the liver and are excreted, either as unchanged
compound or in the Íbrm of metabolites, into the bile. The role of the liver in the
distribution, elimination and time course of action of NMBA's can be elucidated
by temporarily excluding the liver lrom the sysÍemic circulation by means of a
portocaval shunt and clamping of the hepatic portal vein and common hepatic
artery. We investigated 24 NMBA's in this liver shunt model in the cat (Chapter 2).
Temporary exclusion of the liver Íiom the systemic circulation demonstrated that
the liver plays an important role in the distribution and/or elimination of NMBA's.
Exclusion of the liver prolonged the duration Ío 90oÁ recovery of all of the
investigated NMBA's. Similar experiments in the pig with additional sampling of
blood showed that exclusion of the liver prolonged the duration of action to 90%
recovery and at the same time decreased the rate of plasn-ra concentration decay of
rocuronium. When the normal circulation was restored, i.e., the liver included in
the systemic circulation, the plasma concentration decreased rapidly. In the search
for physico-chemical properties promoting hepatic uptake, a trend was found for
the more lipophilic agents to be taken up by the liver more extensively than the less
lipophilic agents. No trend was found between the degree of protein binding of the
NMBA's tested and their hepatic uptake.
In humans, however, such a study cannot be performed: alternatively,
controlled hypothermia, a condition frequently applied in human patients, could be
used to investigate the role of the liver in the offset of neuromuscular block. It has
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long been recognized that hypothermia prolongs the time course of action of non-
depolarizing NMBA's. The various mechanisms that may underly this
prolongation, however, are not known. Since the time course of action of NMBA's,
i.e. pharmacokinetics and/or pharmacodynamics. is mainly determined by a
redistribution process, a major contribution of a pharmacokinetic mechanism to
this phenomenon should be considered. We therefore hypothesized that the
hypothermia-induced prolongation of the time course of these NMBA's results
from a change in their pharmacokinetics, i.e. a reduced plasma clearance. To test
our hypothesis, we detennined the influence of hypothermia (surface cooling) on
the time-course of action and on the pharmacokinetics of rocuronium in humans
(Chapter 7). Hypothermia prolonged the duration of action of rocuronium and
delayed its spontaneous recovery of block. Altered pharmacokinetics, i.e., a
decreased plasma clearance in the hypothermic patients in combination with an
unchanged volume of distribution, can explain the prolongation of the duration of
action. Consequently, the dose requirement of rocuronium under hypothermia is
largely decreased, which makes dosing based on the results obtained from
monitoring of the muscle response obligatory.
If hypothermia prolongs the time course of action of NMBA's via an effect on
the pharmacokinetics, does perturbation of the liver uptake then play a role in this
change in pharmacokinetics? or, Is the pharmacokinetic change based on a reduced
rate oÍ'extrahepatic distribution, for instance due to a reduced cardiac output and
muscle blood flow and/or on a reduced rate of metabolism? To elucidate the
mechanism of the hypothermia-induced prolongation of NMBA's, we used an
isolated perfused rat liver model in which the liver perfusion rate can be
maintained fairly constant and other organs that are important for distribution or
elimination are absent. Since in clinical practice, hypothermia may occur either
alone or in combination rvith acidosis or hypoxia we also investigated the influence
of these conditions on the net hepatic uptake, i.e. the difference between uptake
and release, and on the biliary excretion of vecuronium. In addition, we determined
the influence of temperature on the metabolic conversion of vecuronium in bile and
liver homogenate. Since uptake in mitochondria is an important aspect of hepatic
storage, we also studied the influence of hypothermia on the uptake of vecuronium
in isolated rat liver mitochondria. Finally. computer-aided simulations were
performed in order to analyze the observed changes and to study the relative
influence of these conditions on the hepatic net uptake, metabolism and biliary
excretion (Chapter 8). Hypothermia and acidosis both reversibly reduced the net
uptake of vecuronium by the liver. Hypothermia also reduced the rate of
vecuronium metabolism. Hypoxia only slightly, but irreversibly, reduced the net
uptake but largely affected biliary excretion. Interestingly, whereas hypothermia
reduced the net uptake of vecuronium in the liver extensively, its biliary excretion
virtually remained intact. Apparently, the reduction in the rate of metabolism
results in maintaining the concentration of the parent compound in the liver in spite
of the decreased uptake rate, thus maintaining the concentration gradient between
liver and bile. Due to the reduced conversion of vecuronium to its 3-desacetyl
metabolite, hypothermia led to a drastic reduction in the biliary excretion rate of 3-
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desacetyl vecuronium. Reasonable fits in the hypothermia experiments and to a
lesser extent in the acidosis experiments. could only be obtained when the rate
constants for hepatic uptake and rnetabolism of vecuronium rvere allowed to
decrease during the period of hypothennia or acidosis. The effects of acidosis may
have been due to a pH-induced increase in the degree of protonation of the tertiary
amino group of vecuronium, which could have reduced the efficacy of carrier-
mediated transport. In the hypoxia experiments, reduction of the concentration of
oxygen in the gassing mixture to only 70% did not lead to gross deterioration of
liver function according to the usual viability criteria. However, biliary excretion of
vecuroniuur rvas lor.vered abruptly and extensively while excretion was not
resumed at returning to normal oxygenation. Most likely, irreversible liver damage
had occuned specifically reflected in perturbation of the biliary excretion step.
The total recovenr' of vecuronium from perfusion medium, bile and liver at the
end of the experiment was 720Á (61 - 86) for all l iver perfusions, and did not diÍfer
in the control. hypothermia. acidosis or hypoxia experirnents. This recovery value
is significantly lower than reported in other studies. Our steady state/continuous
infusion study design, hor'r'ever, differed from the single bolus studies that are
commonly employed. We speculated that the persistent presence of the NMBA in
the l iver could lead to storage in a deep (non-extractable) compartment. By means
of bolus administration of vecuronium in additional l iver perfusion experiments,
we obtained the same high total recovery as c'rther investigators and we showed that
the storage process only temporarily prevents the drug from being extracted. This
isolated perfused rat liver study shows that hypothermia extensively, and acidosis
to a lesser extent, inl'luences the phannacokinetics of vecuronium and emphasizes
the need for effect measurement o1 NMBA's in patients during hypothermia to
prevent overdosing.
Collectivel.v. the data presented in this thesis indicate that the lung does not
have a prominent role in the pharmacokinetics and time course of action of
NMBA's. In contrast, the l iver plays a prominent role in the pharmacokinetics of
many NMBA's and is an important factor in both the onset and oÍfset of block,
either by synthesizing plasma cholinesterase that catalvzes the degradation of some
NMBA's or by rapid hepatic uptake, metabolism or biliary excretion of other
NMBA's.
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